3 reasons why I’m bullish on ResMed Inc. (CHESS)

There are plenty of high-quality ASX healthcare stocks with CSL Limited (ASX: CSL) and Cochlear Limited (ASX: COH) prominent among them.

One stock that I am particularly bullish on is RESMED/IDR UNRESTR (ASX: RMD) also known as just ResMed.

There are plenty of reasons to like this San Diego-based company, but here are my five:

Leader of a large untapped market

With more than 4 million cloud connected devices and software solutions that help the company monitor their patients remotely, treat and manage sleep apnoea, ResMed is a clear leader in this niche market.

Industry estimates are that 12 million Americans suffer from sleep apnoea and less than 4 million of them are diagnosed or treated for it each year. There is plenty of long term growth opportunities in America alone, never mind internationally.


ResMed was founded by its current Chairman Peter Farrell and his son Mick Farrell, who has been a ResMed employee for over 15 years, and is the current CEO. Together they have led the company and seen its share price increase by over 3 times in the last six years.

Their wealth, reputation and legacy is all tied into the business which aligns their interest in growing the business with shareholder interests.

Technology and innovation

ResMed has been innovative and at the forefront of embracing new technology trends. One such trend is cloud computing and the acquisition of Brightree, a medical software-as-a-service (SAAS) company, has allowed ResMed to  provide more services to doctors managing post-acute illnesses.

Foolish takeaway

With a PE ratio of 30, ResMed shares don’t come cheap and there is a risk that many people who suffer from sleep apnoea might choose not to get treatment. However, there is plenty to like about ResMed and it’s a company I’d be happy to own and hold for the long term as part of a well diversified portfolio.

In addition to ResMed, here are 3 revolutionary companies that I’d love to own.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor Kevin Gandiya has no position in any of the stocks mentioned.

You can follow Kevin on Twitter @KevinGandiya.

The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!